Mesoblast Ltd (ASX:MSB) Share Price

Company Profile

Business description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUS
T: +61 396396036
E: [email protected]
https://www.mesoblast.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
108

Recommended

Morningstar analysts see value in several stocks under fire from shorts.

Lewis Jackson | 12 January 2022

Morningstar had forecast big losses for the drugmaker, which has been dropped from the ASX 200.

Emma Rapaport | 15 June 2020

The biotech giant has jumped 22pc a year for the past decade but new players are emerging.

Nicki Bourlioufas | 07 April 2019

Index	Last price	Change	% Change
All Ordinaries	9,144.70	60.50	-0.66%
CAC 40	8,139.00	66.37	-0.81%
DAX 40	25,820.36	504.65	-1.92%
Dow JONES (US)	51,285.73	237.33	-0.46%
FTSE 100	10,673.94	108.72	-1.01%
HKSE	24,481.86	315.12	-1.27%
NASDAQ	24,579.43	264.43	1.09%
Nikkei 225	57,434.77	3,643.13	-5.96%
NZX 50 Index	13,998.50	92.47	-0.66%
S&P 500	7,376.86	23.13	0.31%
S&P/ASX 200	9,020.80	44.30	-0.49%
SSE Composite Index	3,649.18	40.73	-1.10%